{"id":647567,"date":"2023-04-17T18:02:02","date_gmt":"2023-04-17T18:02:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=647567"},"modified":"2023-04-17T18:02:02","modified_gmt":"2023-04-17T18:02:02","slug":"cutaneous-tcell-lymphoma-ctcl-pipeline-assessment-2023-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-and-ema-approvals-competitive-landscape-and-key-companies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cutaneous-tcell-lymphoma-ctcl-pipeline-assessment-2023-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-and-ema-approvals-competitive-landscape-and-key-companies_647567.html","title":{"rendered":"Cutaneous T-Cell Lymphoma (CTCL) Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA and EMA Approvals, Competitive Landscape, and Key Companies"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cutaneous T-Cell Lymphoma (CTCL) Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA and EMA Approvals, Competitive Landscape, and Key Companies\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Cutaneous T-Cell Lymphoma (CTCL) Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA and EMA Approvals, Competitive Landscape, and Key Companies\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, globally, about 25+ key pharma and biotech companies are working on 27+ pipeline drugs in the Cutaneous T-Cell Lymphoma (CTCL) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;<strong>Cutaneous T-Cell Lymphoma (CTCL)&nbsp;<\/strong><strong>Pipeline Insight, 2023<\/strong>&rdquo; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Cutaneous T-Cell Lymphoma Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Cutaneous T-Cell Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Cutaneous T-Cell Lymphoma Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/8fdad738d4aed9ed6789a8d4e92e20fa.jpg\" alt=\"Cutaneous T-Cell Lymphoma Pipeline Analysis\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Cutaneous T-Cell Lymphoma (CTCL) Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights into the emerging therapies for the <strong>treatment of Cutaneous T-Cell Lymphoma<\/strong> and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the <strong>Cutaneous T-Cell Lymphoma market.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis of Emerging Therapies by Phases<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report covers the emerging products under different phases of clinical development like<\/strong> &#8211;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late-stage products (Phase III)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mid-stage products (Phase II)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early-stage product (Phase I)&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cutaneous T-Cell Lymphoma (CTCL) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intra-articular<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intraocular<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intrathecal&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ophthalmic<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Parenteral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subcutaneous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Topical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Transdermal<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Products have been categorized under various Molecule types, such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oligonucleotide<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peptide<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small molecule<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn How the Ongoing Clinical &amp; Commercial Activities will Affect the Cutaneous T-Cell Lymphoma Therapeutic Segment @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>There are approx. <strong>25+ key companies<\/strong> developing therapies for Cutaneous T-Cell Lymphoma. Currently, <strong>Soligenix<\/strong> is leading the therapeutics market with its Cutaneous T-Cell Lymphoma drug candidates in the most advanced stage of clinical development.<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Latest Key Update in the Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market<\/strong><\/p>\n<p style=\"text-align: justify;\">On April 14, 2023,&nbsp;<strong>Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company)<\/strong>&nbsp;announced that the Company convened a&nbsp;<strong>Type A Meeting<\/strong>&nbsp;with the&nbsp;<strong>United States (U.S.) Food and Drug Administration (FDA)<\/strong>. During the Type A Meeting, representatives of the Company and the FDA discussed the contents of a refusal to file (RTF) letter previously issued by the FDA regarding the Company&#8217;s&nbsp;<strong>new drug application (NDA)<\/strong>&nbsp;for&nbsp;<strong>HyBryte&trade; (synthetic hypericin sodium)<\/strong>&nbsp;in the treatment of early-stage<strong>&nbsp;cutaneous T-cell lymphoma (CTCL),<\/strong>&nbsp;rare cancer, where it successfully demonstrated statistically significant results in Phase 3 clinical trial (Study HPN-CTCL-01; also referred to as the FLASH study).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Leading Players in the Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Include:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>4SC AG, Angimmun, Astex Pharmaceuticals, BeiGene, Bio-Path Holdings, BioInvent International AB, Bioniz Therapeutics, Citius Pharmaceuticals, Codiak BioSciences, Elorac Equillium, Galderma R&amp;D, Genzada Pharmaceuticals, Hoffmann-La Roche, Innate Pharma, Jiangsu Simcere Pharmaceutical, Kymera Therapeutics, Legend Biotech, Medivir, Merck Sharp &amp; Dohme Corp, miRagen Therapeutics, Myeloid Therapeutics, Otsuka Pharmaceuticals, Philogen, Scopus BioPharma, Soligenix, Sorrento Therapeutics, VidacPharma, Viridian Therapeutics, and others.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cutaneous T-Cell Lymphoma (CTCL) Emerging and Marketed Drugs Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Adcetris (Brentuximab Vedotin): Seagen<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">BNZ-1: Bioniz<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">exoIL-12: Codiak<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">HyBryte (SGX301): Soligenix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">I\/ONTAK (E7777): Citius Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lacutamab (IPH4102): Innate Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Potelegio (Mogamulizumab-kpkc): Kyowa Hakko Kirin<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Resminostat: 4SC AG<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">SGX301: Soligenix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Targretin (Bexarotene): Valeant Pharmaceuticals\/ Bausch Health<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Uvadex (Methoxsalen): Mallinckrodt Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Valchlor\/Ledaga (Mechlorethamine): Helsinn Therapeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many More<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Cutaneous T-Cell Lymphoma Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Cutaneous T-Cell Lymphoma &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Cutaneous T-Cell Lymphoma Late-Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Cutaneous T-Cell Lymphoma Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Cutaneous T-Cell Lymphoma Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Cutaneous T-Cell Lymphoma Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Cutaneous T-Cell Lymphoma Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Key Companies in the Cutaneous T-Cell Lymphoma Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Cutaneous T-Cell Lymphoma Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Cutaneous T-Cell Lymphoma Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Cutaneous T-Cell Lymphoma Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Cutaneous T-Cell Lymphoma Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF to Explore the Key Offerings of the Report:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/consulting\/partner-identification-services\">Healthcare Partner Identification Strategies<\/a><\/strong><\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cutaneous-tcell-lymphoma-ctcl-pipeline-assessment-2023-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-and-ema-approvals-competitive-landscape-and-key-companies\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cutaneous-tcell-lymphoma-ctcl-pipeline-assessment-2023-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-and-ema-approvals-competitive-landscape-and-key-companies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP As per DelveInsight\u2019s assessment, globally, about 25+ key pharma and biotech companies are working on 27+ pipeline drugs in the Cutaneous T-Cell Lymphoma (CTCL) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cutaneous-tcell-lymphoma-ctcl-pipeline-assessment-2023-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-and-ema-approvals-competitive-landscape-and-key-companies_647567.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,426,417,406,404],"tags":[],"class_list":["post-647567","post","type-post","status-publish","format-standard","hentry","category-Business","category-Financial-Market","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/647567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=647567"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/647567\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=647567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=647567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=647567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}